Shanghai - Delayed Quote CNY

BeiGene, Ltd. (688235.SS)

230.50

+6.62

+(2.96%)

At close: 3:00:02 PM GMT+8

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene (NasdaqGS:ONC) recently announced comprehensive analyses from clinical trials at EHA2025, focusing on hematological malignancies, reflecting its commitment to advancing treatment options. However, the company’s share price declined by 2.46% over the last quarter. Despite the unveiling of promising clinical data and revenue growth, these developments seem to have countered broader market trends, where major indices like the S&P 500 and Nasdaq Composite showed gains. BeiGene's improved...

Simply Wall St. 23 hours ago

BEIGF

ONC
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

SAN CARLOS, Calif., May 14, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUK

Business Wire yesterday

BEIGF

ONC
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

SAN CARLOS, Calif., May 13, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.

Business Wire 3 days ago

BEIGF

ONC
BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

BeiGene ( NASDAQ:ONC ) First Quarter 2025 Results Key Financial Results Revenue: US$1.12b (up 49% from 1Q 2024). Net...

Simply Wall St. 5 days ago

BEIGF

ONC
Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Last week, you might have seen that BeiGene, Ltd. ( NASDAQ:ONC ) released its first-quarter result to the market. The...

Simply Wall St. 6 days ago

BEIGF

ONC
BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Lei Zhang’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against other billionaire Lei Zhang’s stock picks with huge upside potential. Lei Zhang and Hillhouse Capital: Quiet Power in Asian Investing Lei Zhang, […]

Insider Monkey 7 days ago

ONC
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

BeiGene Ltd (ONC) marks a milestone with its first GAAP profitability, driven by a 49% revenue increase and strong market performance of Brukinsa.

GuruFocus.com 8 days ago

ONC
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 9 days ago

ONC
BeiGene Announces First Quarter 2025 Financial Results and Business Updates

SAN CARLOS, Calif., May 07, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

Business Wire 9 days ago

BEIGF

ONC
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

SAN CARLOS, Calif., April 29, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.

Business Wire 16 days ago

BEIGF

ONC
3 Stocks That Could Be Trading Below Their Estimated Fair Value

Over the last 7 days, the United States market has risen by 7.1%, contributing to a 7.7% increase over the past year, with earnings growth anticipated at 14% per annum in the coming years. In this environment, identifying stocks that may be trading below their estimated fair value can offer potential opportunities for investors looking to capitalize on future growth prospects.

Simply Wall St. 17 days ago

BEIGF

ONC

WIX
Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Investor's Business Daily 22 days ago

BEIGF

ONC
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with these positive long-term market trends.

Simply Wall St. 23 days ago

NBIX

BEIGF

ONC
BeiGene to Announce First Quarter 2025 Financial Results on May 7

SAN CARLOS, Calif., April 17, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.

Business Wire 29 days ago

BEIGF

ONC
BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the European Medicines Agency's positive opinion on TEVIMBRA, recommended for small cell lung cancer treatment, and its recent addition to the Hang Seng China Enterprises Index. These developments underscore BeiGene's expanding presence and potential in the competitive oncology market, providing a...

Simply Wall St. last month

BEIGF

ONC
BeiGene halts ociperlimab amid poor Phase III trial predictions

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune responses against cancer.

Clinical Trials Arena last month

ONC
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif., April 03, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

Business Wire last month

BEIGF

ONC
Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

Amid recent market volatility, driven by concerns over new tariffs and economic data, investors are keenly observing stocks that may be undervalued in the current climate. Identifying stocks priced below their estimated fair value can offer potential opportunities for those looking to navigate these uncertain times effectively.

Simply Wall St. last month

NFG

DRVN

BEIGF
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

SAN CARLOS, Calif., March 31, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lun

Business Wire last month

BEIGF

ONC
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 with BeiGene Ltd's (NASDAQ:ONC) PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early signs of anti-tumor activity. Initial participants will first receive one week of Decoy20 monotherapy intravenously before starting the combination treatment with Decoy20 + tislel

Benzinga last month

ONC

Performance Overview

Return	688235.SS	HANG SENG INDEX (^HSI)
YTD	+43.15%	+16.38%
1-Year	+75.11%	+20.48%
3-Year	+174.54%	+17.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BeiGene, Ltd. (688235.SS)

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Exploring 3 High Growth Tech Stocks In The US Market

BeiGene to Announce First Quarter 2025 Financial Results on May 7

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene halts ociperlimab amid poor Phase III trial predictions

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

Performance Overview